SLC16A3 and carcinoma: Pharmacological inhibition of HIF-1α and ROS, two main drivers of glycolysis in CAFs, partially revert the glycolytic phenotype by rescuing IDH3α and downregulating MCT4 expression in fibroblasts and reduce aggressiveness of ADT carcinoma cells.